Trialbee Partners With Savvy Cooperative
Trialbee has announced a strategic partnership with Savvy Cooperative. This partnership primarily addresses two pain points for patients—the challenge of finding appropriate clinical trials and the lack of opportunity to express their experiences to the industry as consumers of healthcare—an area still ripe for disruption.
As a practical example, Savvy Cooperative members will be introduced to specific clinical trials with an invitation to participate in pre-screening and referral to sites via the Trialbee Honey platform. At the end of the process, all potential participants who come through Honey, regardless of channel, will be invited to join the #AskPatients™ community to share their experiences for future research. While the collaboration is inclusive of all members in the Savvy community, lupus and multiple sclerosis have been selected as pilot indications to demonstrate the power of the partnership as these patients are simultaneously active yet traditionally under recruited.
Reference
Trialbee Partners with Savvy Cooperative to Bring the Voice of the Patient into Clinical Trials Earlier. (2023, March 29). Cision PRWeb.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
